Company Nexus BioPharma, Inc.

Nexus Biopharma, Inc., formerly Plata Resources, Inc., is engaged in developing a weight loss drug that activates the 5' adenosine monophosphate-activated protein kinase (AMPK) metabolic pathway. The Company is developing a treatment for obesity. It has worked for the virtual screening, assay development and optimization, compound selection and screening, and active-to-hit work to support hit identification of inhibitors of Fyn kinase. It is also focused on developing a drug for the blood chemistry improvements for type 2 diabetes. The Company has completed pre-clinical trials of the pharmaceutical activation of AMPK metabolic pathway. The Company focuses on advancing these to pre-Investigational New Drug (IND) trials in preparation for the United States Food and Drug Administration (FDA) human trials of a drug.